Reverse Vaccine Strikes Blow Against Type I Diabetes
Tolerion Inc. reported Phase II results showing promising disease-modifying activity of its lead product TOL-3021 against Type I diabetes.
The product preserved pancreatic beta-cell function while reducing T-cell activity in patients with the disease, as published in Science Translational Medicine.
The product is a "reverse" vaccine designed to selectively suppress specific elements of the immune system that are inappropriately activated in Type I diabetes.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter